{"id":"W3016962124","doi":"10.1136/ejhpharm-2020-eahpconf.198","title":"4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Lung cancer; Nivolumab; Atezolizumab; Chemotherapy; Performance status; Retrospective cohort study; Cancer; Adverse effect; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001858653,0.0004067069,0.001246155,0.0006261292,0.0003322566,0.0006930748,0.0003972228,0.0009291038,0.01419815],"category_scores_gemma":[0.002626511,0.0001813873,0.002869704,0.0006232027,0.0003539491,0.0006685653,0.0004195853,0.0017221,0.001255794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008513579,"about_ca_system_score_gemma":0.001103358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001148711,"about_ca_topic_score_gemma":0.005437338,"domain_scores_codex":[0.9987485,0.0006952782,0.0001823666,0.000123865,0.0001688231,0.00008112151],"domain_scores_gemma":[0.9989643,0.0004312731,0.0002368266,0.00005363382,0.0001820163,0.0001319442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0873738,0.002983839,0.0065691,0.04938037,0.009459468,0.0002225305,0.0001588147,0.0009634386,0.006493407,0.001476793,0.02311732,0.811801],"study_design_scores_gemma":[0.4037785,0.1863242,0.06957273,0.03135037,0.02012103,0.002455821,0.000514928,0.002048798,0.01161774,0.002519232,0.2695515,0.0001450572],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.4850872,0.4203431,0.002426339,0.01083951,0.004700363,0.006859266,0.008909286,0.0004164821,0.06041845],"genre_scores_gemma":[0.9070287,0.06677804,0.002681601,0.005676565,0.0008855957,0.003131848,0.003807011,0.00003814756,0.00997252],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01419815,"threshold_uncertainty_score":0.04749757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05666603131101178,"score_gpt":0.381958387943695,"score_spread":0.3252923566326832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}